US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sionna Therapeutics

20.43

-0.5100-2.44%

Post-market: 20.430.00000.00%16:04 EDT

Volume:51.64K

Turnover:1.06M

Market Cap:900.80M

PE:-3.00

High:20.87

Open:20.87

Low:20.12

Close:20.94

Loading ...

Overview Company News Filings

TPG GP A, LLC Reports Acquisition of Common Shares in Sionna Therapeutics Inc

Sionna Therapeutics Holds Annual Stockholders Meeting

Sionna Therapeutics Announces Advancement of SION-719 and SION-451 to Next Stage of Clinical Trials for Cystic Fibrosis Treatment

Sionna Therapeutics announces data from Phase 1 trials of SION-719, SION-451

Sionna Therapeutics Announces Positive Phase 1 Results and Advances Clinical Trials for NBD1 Stabilizers in Cystic Fibrosis Treatment

Sionna Therapeutics- Sion-719 and Sion-451 Were Generally Well Tolerated and Achieved Desired Pharmacokinetic Targets

THOMSON REUTERS

Sionna Therapeutics Inc -Next Trials to Initiate in Second Half of 2025 With Topline Data Expected in Mid-2026

THOMSON REUTERS

Sionna Therapeutics Announces Positive Phase 1 Data for Nbd1 Stabilizers Sion-719 and Sion-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis

THOMSON REUTERS

Sionna Therapeutics to Participate in Fireside Chat at Goldman Sachs Annual Global Healthcare Conference

TD Cowen Sticks to Its Buy Rating for Sionna Therapeutics, Inc. (SION)

Sionna Therapeutics Q1 EPS $(0.62) Misses $(0.44) Estimate

Press Release: Sionna Therapeutics Reports First Quarter 2025 Financial Results

TD Cowen Sticks to Their Buy Rating for Sionna Therapeutics, Inc. (SION)

Sionna Therapeutics Q4 EPS $(3.38) Up From $(3.93) YoY

Sionna Therapeutics - Qtrly Loss per Share $3.38

THOMSON REUTERS

Press Release: Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Sionna Therapeutics, Inc. (SION): Among Top Insider Purchases Last Month

U.S. RESEARCH ROUNDUP-Accolade, CrowdStrike, Marriott International

Sionna Therapeutics Inc : TD Cowen Initiates Coverage With Buy Rating

THOMSON REUTERS

Sionna Therapeutics initiated with a Buy at TD Cowen

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SION/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SION","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SION\",,,,,undefined,":{"symbol":"SION","market":"US","secType":"STK","nameCN":"Sionna Therapeutics","latestPrice":20.43,"timestamp":1752264000000,"preClose":20.94,"halted":0,"volume":51638,"hourTrading":{"tag":"盘后","latestPrice":20.43,"preClose":20.43,"latestTime":"16:04 EDT","volume":546,"amount":11154.78,"timestamp":1752264245296},"delay":0,"floatShares":11163004,"shares":44092117,"eps":-6.81129,"marketStatus":"Market Closed","change":-0.51,"latestTime":"07-11 16:00:00 EDT","open":20.87,"high":20.87,"low":20.115,"amount":1055449.4451,"amplitude":0.036055,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-6.81129,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1752480000000},"marketStatusCode":7,"adr":0,"listingDate":1738904400000,"exchange":"NASDAQ","adjPreClose":20.94,"postHourTrading":{"tag":"盘后","latestPrice":20.43,"preClose":20.43,"latestTime":"16:04 EDT","volume":546,"amount":11154.78,"timestamp":1752264245296},"volumeRatio":0.3568605014127307},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SION\",,,,,undefined,":{"symbol":"SION","floatShares":11163004,"roa":"-37.10%","roe":"-61.44%","lyrEps":-15.986072,"volumeRatio":0.3568605014127307,"shares":44092117,"dividePrice":0,"high":20.87,"amplitude":0.036055,"preClose":20.94,"low":20.115,"week52Low":7.255,"pbRate":"2.56","week52High":25.19,"institutionHeld":0,"latestPrice":20.43,"eps":-6.81129,"divideRate":0,"volume":51638,"delay":0,"ttmEps":-6.81129,"open":20.87,"prevYearClose":18,"prevWeekClose":21.19,"prevMonthClose":17.35,"prevQuarterClose":17.35,"fiveDayClose":21.19,"twentyDayClose":17.26,"sixtyDayClose":8.91},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SION\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2548288055","title":"TPG GP A, LLC Reports Acquisition of Common Shares in Sionna Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2548288055","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548288055?lang=en_us&edition=fundamental","pubTime":"2025-07-02 05:03","pubTimestamp":1751403834,"startTime":"0","endTime":"0","summary":"TPG GP A, LLC, a beneficial owner, reported an acquisition of common shares of Sionna Therapeutics Inc. The form was filed by more than one reporting person, including TPG GP A, LLC, among other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sionna Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 01, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nNDL1JBmp6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SION","BK4139"],"gpt_icon":0},{"id":"2543630481","title":"Sionna Therapeutics Holds Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2543630481","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543630481?lang=en_us&edition=fundamental","pubTime":"2025-06-14 04:32","pubTimestamp":1749846764,"startTime":"0","endTime":"0","summary":"Sionna Therapeutics, Inc. ( ($SION) ) has provided an update. On June 12, 2025, Sionna Therapeutics, Inc. held its Annual Meeting of Stockholders, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sionna-therapeutics-holds-annual-stockholders-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sionna-therapeutics-holds-annual-stockholders-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SION"],"gpt_icon":0},{"id":"2541286988","title":"Sionna Therapeutics Announces Advancement of SION-719 and SION-451 to Next Stage of Clinical Trials for Cystic Fibrosis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2541286988","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541286988?lang=en_us&edition=fundamental","pubTime":"2025-06-06 23:00","pubTimestamp":1749222018,"startTime":"0","endTime":"0","summary":"Sionna Therapeutics Announces Advancement of SION-719 and SION-451 to Next Stage of Clinical Trials for Cystic Fibrosis Treatment. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sionna Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on June 06, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDL6KHTD8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00B64PRP62.GBP","BK4588","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4112","IE00BGHQF748.EUR","LU2095319765.USD","NDAQ","LU2210149790.SGD","BK4585","SION","BK4139"],"gpt_icon":0},{"id":"2540694068","title":"Sionna Therapeutics announces data from Phase 1 trials of SION-719, SION-451","url":"https://stock-news.laohu8.com/highlight/detail?id=2540694068","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540694068?lang=en_us&edition=fundamental","pubTime":"2025-06-04 19:11","pubTimestamp":1749035473,"startTime":"0","endTime":"0","summary":"Sionna Therapeutics (SION) announced positive data from its Phase 1 clinical trials of SION-719 and SION-451, the company’s first-in-class nucleoti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sionna-therapeutics-announces-data-from-phase-1-trials-of-sion-719-sion-451-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sionna-therapeutics-announces-data-from-phase-1-trials-of-sion-719-sion-451-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SION","BK4139"],"gpt_icon":0},{"id":"2540996050","title":"Sionna Therapeutics Announces Positive Phase 1 Results and Advances Clinical Trials for NBD1 Stabilizers in Cystic Fibrosis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2540996050","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540996050?lang=en_us&edition=fundamental","pubTime":"2025-06-04 19:00","pubTimestamp":1749034816,"startTime":"0","endTime":"0","summary":"Sionna Therapeutics Announces Positive Phase 1 Results and Advances Clinical Trials for NBD1 Stabilizers in Cystic Fibrosis Treatment. Sionna Therapeutics Inc., a biopharmaceutical company focused on advancing treatments for cystic fibrosis, announced positive results from Phase 1 clinical trials for its NBD1 stabilizers, SION-719 and SION-451. These trials, conducted in healthy volunteers, demonstrated that both stabilizers were generally well tolerated and achieved desired pharmacokinetic targets, supporting their potential as add-ons to current standard care or in combination with other modulators. Sionna plans to progress SION-719 into a Phase 2a proof-of-concept trial for cystic fibrosis patients and SION-451 into a Phase 1 dual combination trial, both set to commence in the latter half of 2025. The company aims to release topline data from these trials by mid-2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL15PzWn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SION","LU2210149790.SGD","IE00BKPKM429.USD","NDAQ","BK4139","IE00BGHQF748.EUR","LU2210150020.SGD","IE00B64PRP62.GBP","LU2095319765.USD","BK4585","IE00B3QW5Z07.USD","BK4112","BK4588"],"gpt_icon":0},{"id":"2540205014","title":"Sionna Therapeutics- Sion-719 and Sion-451 Were Generally Well Tolerated and Achieved Desired Pharmacokinetic Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=2540205014","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540205014?lang=en_us&edition=fundamental","pubTime":"2025-06-04 19:00","pubTimestamp":1749034807,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S707B:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SION","BK4139"],"gpt_icon":0},{"id":"2540112050","title":"Sionna Therapeutics Inc -Next Trials to Initiate in Second Half of 2025 With Topline Data Expected in Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2540112050","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540112050?lang=en_us&edition=fundamental","pubTime":"2025-06-04 19:00","pubTimestamp":1749034807,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S707B:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SION","BK4139"],"gpt_icon":0},{"id":"2540050101","title":"Sionna Therapeutics Announces Positive Phase 1 Data for Nbd1 Stabilizers Sion-719 and Sion-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2540050101","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540050101?lang=en_us&edition=fundamental","pubTime":"2025-06-04 19:00","pubTimestamp":1749034807,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S707B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SION","BK4139"],"gpt_icon":0},{"id":"2540775967","title":"Sionna Therapeutics to Participate in Fireside Chat at Goldman Sachs Annual Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2540775967","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540775967?lang=en_us&edition=fundamental","pubTime":"2025-06-03 19:00","pubTimestamp":1748948435,"startTime":"0","endTime":"0","summary":"Sionna Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing novel medicines for cystic fibrosis, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference. The event is scheduled for June 11, 2025, at 8:00 a.m. ET in Miami, Florida. A live webcast and replay of the presentation will be available on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sionna Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on June 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL2G8KDS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1668664300.SGD","LU2237443465.HKD","LU2471134879.HKD","LU2237443622.USD","LU2471134796.USD","LU1868837136.USD","BK4533","LU1868836757.USD","LU1894683348.USD","IE0002270589.USD","IE0034235188.USD","LU2237443382.USD","IE00B19Z3581.USD","LU0061475181.USD","BK4552","IE00BKPKM429.USD","LU1868836914.USD","BK4127","IE0004086264.USD","IE00BSNM7G36.USD","NDAQ","IE00BFXG1179.USD","LU2237443978.SGD","LU0048573561.USD","LU0106831901.USD","LU2210149790.SGD","IE00BGHQF748.EUR","LU2471134952.CNY","BK4139","IE00B19Z3B42.SGD","LU2471134523.USD","LU2210150020.SGD","BK4550","LU0251142724.SGD","LU1791807156.HKD","BK4585","LU2095319765.USD","SION","LU1868837300.USD","LU1894683264.USD","LU2750360641.GBP","LU0096364046.USD","LU0251131958.USD","LU2750360997.AUD","BK4504","LU2237443895.HKD","LU2237438978.USD","IE00B3QW5Z07.USD","IE0004091025.USD","BK4516"],"gpt_icon":0},{"id":"2535893777","title":"TD Cowen Sticks to Its Buy Rating for Sionna Therapeutics, Inc. (SION)","url":"https://stock-news.laohu8.com/highlight/detail?id=2535893777","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535893777?lang=en_us&edition=fundamental","pubTime":"2025-05-13 03:55","pubTimestamp":1747079710,"startTime":"0","endTime":"0","summary":"In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Sionna Therapeutics, Inc. (SION – Research Report). The company’s s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-sticks-to-its-buy-rating-for-sionna-therapeutics-inc-sion?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-sticks-to-its-buy-rating-for-sionna-therapeutics-inc-sion?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TD","SION","COWN"],"gpt_icon":0},{"id":"2534266522","title":"Sionna Therapeutics Q1 EPS $(0.62) Misses $(0.44) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2534266522","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534266522?lang=en_us&edition=fundamental","pubTime":"2025-05-12 19:14","pubTimestamp":1747048499,"startTime":"0","endTime":"0","summary":"Sionna Therapeutics (NASDAQ:SION) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.44) by 40.91 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45344041/sionna-therapeutics-q1-eps-0-62-misses-0-44-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SION"],"gpt_icon":0},{"id":"2534223775","title":"Press Release: Sionna Therapeutics Reports First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2534223775","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534223775?lang=en_us&edition=fundamental","pubTime":"2025-05-12 19:00","pubTimestamp":1747047600,"startTime":"0","endTime":"0","summary":"Phase 1 dosing completed for NBD1 stabilizers SION-719 & SION-451; both compounds continue to be generally well tolerated. On track to initiate Phase 2a proof-of-concept trial and at least one dual combination MAD trial in the second half of 2025; topline data for both anticipated in mid-2026. Strong cash position following completed upsized IPO, with approximately $354.7 million in cash and cash equivalents, expected to fund operations into 2028. \"Following our upsized IPO in February, we are in a strong financial position to advance our mission to transform the treatment paradigm for patients with CF,\" said Mike Cloonan, President and Chief Executive Officer of Sionna. \"We continue to execute across our pipeline and have completed dosing in our Phase 1 trials for both SION-719 and SION-451. We look forward to announcing topline data from these trials this quarter, and to initiating our Phase 2a POC trial and the combination MAD Phase 1 program later this year. With multiple meaningfu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4213","IPO","BK4588","CF","BK4585","SION","BK4093","SOC"],"gpt_icon":0},{"id":"2521255434","title":"TD Cowen Sticks to Their Buy Rating for Sionna Therapeutics, Inc. (SION)","url":"https://stock-news.laohu8.com/highlight/detail?id=2521255434","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521255434?lang=en_us&edition=fundamental","pubTime":"2025-03-22 02:55","pubTimestamp":1742583350,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Ritu Baral maintained a Buy rating on Sionna Therapeutics, Inc. (SION – Research Report) today. The company’s shares opened today ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-sticks-to-their-buy-rating-for-sionna-therapeutics-inc-sion?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-sticks-to-their-buy-rating-for-sionna-therapeutics-inc-sion?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COWN","SION","TD"],"gpt_icon":0},{"id":"2520043069","title":"Sionna Therapeutics Q4 EPS $(3.38) Up From $(3.93) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2520043069","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520043069?lang=en_us&edition=fundamental","pubTime":"2025-03-20 19:18","pubTimestamp":1742469488,"startTime":"0","endTime":"0","summary":"Sionna Therapeutics Q4 EPS $(3.38) Up From $(3.93) YoY","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44413626/sionna-therapeutics-q4-eps-3-38-up-from-3-93-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Sionna Therapeutics Q4 EPS $(3.38) Up From $(3.93) YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SION"],"gpt_icon":0},{"id":"2520374454","title":"Sionna Therapeutics - Qtrly Loss per Share $3.38","url":"https://stock-news.laohu8.com/highlight/detail?id=2520374454","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520374454?lang=en_us&edition=fundamental","pubTime":"2025-03-20 19:00","pubTimestamp":1742468402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nTUA9HJBBJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SION"],"gpt_icon":0},{"id":"2520437381","title":"Press Release: Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2520437381","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520437381?lang=en_us&edition=fundamental","pubTime":"2025-03-20 19:00","pubTimestamp":1742468400,"startTime":"0","endTime":"0","summary":"Phase 1 MAD dosing completed for SION-451 and final MAD cohort of SION-719 planned; Interim data in healthy volunteers show potential to provide clinically meaningful benefit to CF patients. Topline data anticipated in first half of 2025. On track to initiate NBD1 Phase 2a proof-of-concept trial in combination with SOC in CF patients and combination MAD trials of an NBD1 stabilizer with a complementary modulator in healthy volunteers in the second half of 2025, with topline data for both anticipated in mid-2026. Completed upsized IPO with gross proceeds of approximately $219 million, extending runway into 2028","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4181","BK4093","BK4588","PK","BK4218","BK4213","BK4585","SION","CF","SOC","BK4139"],"gpt_icon":0},{"id":"2519346994","title":"Sionna Therapeutics, Inc. (SION): Among Top Insider Purchases Last Month","url":"https://stock-news.laohu8.com/highlight/detail?id=2519346994","media":"Insider Monkey","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519346994?lang=en_us&edition=fundamental","pubTime":"2025-03-16 04:43","pubTimestamp":1742071388,"startTime":"0","endTime":"0","summary":"We recently published a list of Top 10 Insider Purchases Last Month. In this article, we are going to take a look at where Sionna Therapeutics, Inc.  stands against other top insider purchases last month.How will new tariffs impact the U.S. economy?What’s next on President Trump’s geopolitical agenda?These are some of the concerning questions influencing market conditions.According to J.P. Morgan’s chief global economist, Bruce Kasman, there is about a 40% chance of a U.S. recession and a risk of lasting damage to the country’s reputation as an investment destination, writes Reuters.“Where we stand now is with a heightened concern about the U.S. economy,” Kasman said to reporters in Singapore on Wednesday.Additionally, Goldman Sachs lowered its 2025-end target for the broader market. “The proximate causes of the market decline are the jump in policy uncertainty largely related to tariffs, concerns about the economic growth outlook, and a positioning unwind, especially among hedge funds","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sionna-therapeutics-inc-sion-among-204308018.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2750360997.AUD","BK4585","IE00BFXG1179.USD","LU0096364046.USD","BK4588","LU2237443465.HKD","LU2237443622.USD","LU1868836757.USD","IE00BSNM7G36.USD","LU2471134796.USD","LU2237443382.USD","SION","IE00B19Z3581.USD","BK4533","LU1868836914.USD","LU2750360641.GBP","BK4093","BK4504","LU1668664300.SGD","BK4552","LU2471134879.HKD","BK4139","IE0034235188.USD","IE00B19Z3B42.SGD","IE0004091025.USD","LU2237443895.HKD","LU1868837136.USD","LU1868836591.USD","LU2237443978.SGD","LU1868837300.USD","LU2237443549.SGD","CF","IE0002270589.USD","LU2471134952.CNY","BK4516","LU0106831901.USD","LU1791807156.HKD","LU2237438978.USD","BK4127","BK4550","LU0061475181.USD","IE0004086264.USD","LU2471134523.USD"],"gpt_icon":0},{"id":"2517961079","title":"U.S. RESEARCH ROUNDUP-Accolade, CrowdStrike, Marriott International","url":"https://stock-news.laohu8.com/highlight/detail?id=2517961079","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517961079?lang=en_us&edition=fundamental","pubTime":"2025-03-05 15:53","pubTimestamp":1741161195,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Accolade, CrowdStrike, Marriott InternationalMarch 5 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, includi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nL3N3PO0SE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHH","AKYA","H","BK4539","BK4139","YUM","LU2106854487.HKD","LU2125910336.SGD","LU0211328371.USD","BK4121","ACHC","WM","WDC","TGT","MGA","SION","LU2092937221.SGD","ROST","WH","LU0965508806.USD","BK4560","LU1934455863.HKD","LU1720051017.SGD","HLT","LU2360108059.USD","LU2463526074.USD","SNDK","CHPT","LU0106261612.USD","BBY","ACCD","PASG","LU0240878834.USD","BK4114","MAR","LU0240877869.USD","LU2229751404.USD","LU0965509010.AUD","BOX","LU1934455194.USD","RSG","IE00B894F039.SGD","BK4185","AZO","SGRY","LU2238339852.HKD","LU2237443978.SGD","CRWD","LU2362541513.USD","INGM"],"gpt_icon":1},{"id":"2517957069","title":"Sionna Therapeutics Inc : TD Cowen Initiates Coverage With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2517957069","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517957069?lang=en_us&edition=fundamental","pubTime":"2025-03-05 13:59","pubTimestamp":1741154363,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PO093:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SION","BK4139"],"gpt_icon":0},{"id":"2516367153","title":"Sionna Therapeutics initiated with a Buy at TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2516367153","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516367153?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:36","pubTimestamp":1741095415,"startTime":"0","endTime":"0","summary":"TD Cowen initiated coverage of Sionna Therapeutics (SION) with a Buy rating. Sionna’s pipeline of cystic fibrosis therapies directly target NBD1, w...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sionna-therapeutics-initiated-with-a-buy-at-td-cowen?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sionna-therapeutics-initiated-with-a-buy-at-td-cowen?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4127","BK4585","BK4566","BK4207","TD","SION","COWN"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":47,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SION\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-12","symbol":"SION","fiscalQuarterEnding":"2025/03","expectedEps":-0.45,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"pre","actualEps":-0.62}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SION\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SION\",market:\"US\",delay:true,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":3,"updateTime":1741320000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SION\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:true,algorithm:1,,,undefined,":{"brief":{"id":"SION","date":"2025-07-11","current":-13.921097,"percent":0.141509,"low":-18.418073,"twenty":-12.562594,"median":-9.646376,"eighty":-8.576247,"high":-5.47907,"avg":-10.428338,"sd":2.554508,"marketCap":923288929},"quantilePoints":[{"date":"2025-02-07","current":-13.261013,"twenty":-12.252025,"median":-10.738543,"eighty":-9.22506,"marketCap":765372600},{"date":"2025-02-14","current":-14.940741,"twenty":-16.115077,"median":-14.940741,"eighty":-13.535074,"marketCap":862319796},{"date":"2025-02-21","current":-15.365065,"twenty":-15.365065,"median":-14.763927,"eighty":-14.631317,"marketCap":886810118},{"date":"2025-02-28","current":-11.280197,"twenty":-15.101402,"median":-14.760244,"eighty":-13.045594,"marketCap":651047865},{"date":"2025-03-07","current":-11.960372,"twenty":-15.059369,"median":-14.631317,"eighty":-11.310767,"marketCap":690304817},{"date":"2025-03-14","current":-13.068521,"twenty":-15.036515,"median":-13.072343,"eighty":-11.387191,"marketCap":754262771},{"date":"2025-03-21","current":-10.607665,"twenty":-14.940741,"median":-12.594692,"eighty":-11.280197,"marketCap":612232003},{"date":"2025-03-28","current":-8.569094,"twenty":-14.763927,"median":-12.189644,"eighty":-10.607665,"marketCap":528610240},{"date":"2025-04-04","current":-8.304439,"twenty":-14.75656,"median":-11.44833,"eighty":-8.654927,"marketCap":512284214},{"date":"2025-04-11","current":-5.47907,"twenty":-14.719724,"median":-11.345158,"eighty":-8.304439,"marketCap":337992858},{"date":"2025-04-17","current":-7.152833,"twenty":-14.648998,"median":-11.146455,"eighty":-7.438946,"marketCap":441243940},{"date":"2025-04-25","current":-9.012569,"twenty":-13.535074,"median":-10.607665,"eighty":-7.830921,"marketCap":555967364},{"date":"2025-05-02","current":-9.227154,"twenty":-13.113134,"median":-10.157913,"eighty":-8.049798,"marketCap":569204682},{"date":"2025-05-09","current":-8.991111,"twenty":-13.07005,"median":-9.363058,"eighty":-8.189398,"marketCap":554643632},{"date":"2025-05-16","current":-8.935031,"twenty":-13.050179,"median":-9.227154,"eighty":-8.189398,"marketCap":592598052},{"date":"2025-05-23","current":-8.649163,"twenty":-12.684872,"median":-9.227154,"eighty":-8.258154,"marketCap":573638442},{"date":"2025-05-30","current":-9.380453,"twenty":-12.498397,"median":-9.212848,"eighty":-8.290133,"marketCap":622139770},{"date":"2025-06-06","current":-10.656886,"twenty":-12.42503,"median":-9.227154,"eighty":-8.395596,"marketCap":706796635},{"date":"2025-06-13","current":-11.295102,"twenty":-12.251212,"median":-9.28738,"eighty":-8.459628,"marketCap":749125067},{"date":"2025-06-20","current":-9.792634,"twenty":-12.067794,"median":-9.313972,"eighty":-8.462287,"marketCap":649476883},{"date":"2025-06-27","current":-9.859115,"twenty":-11.920631,"median":-9.377129,"eighty":-8.491142,"marketCap":653886095},{"date":"2025-07-03","current":-14.087299,"twenty":-12.050418,"median":-9.569923,"eighty":-8.540482,"marketCap":934311959},{"date":"2025-07-11","current":-13.921097,"twenty":-12.562594,"median":-9.646376,"eighty":-8.576247,"marketCap":923288929}],"updateTime":1752336678940}}}